Apolipoprotein epsilon-4 allele and the two-year progression of cognitive function in Chinese subjects with late-onset Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 21, Issue 2, 2006, Pages 92-99

  Lam, Linda C W ^a   Tang, Nelson L S ^a   Ma, S L ^a   Lui, Victor W C ^a   Chan, Agnes S Y ^a   Leung, P Y ^a   Chiu, Helen F K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alzheimer's disease; Apolipoprotein E4 allele; Cognitive function; Prospective study

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN EPSILON 4; UNCLASSIFIED DRUG;

AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; CHINESE; CLINICAL DEMENTIA RATING SCALE; COGNITION; DETERIORATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ETHNIC GROUP; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MATTIS DEMENTIA RATING SCALE; MINI MENTAL STATE EXAMINATION; ONSET AGE; PROSPECTIVE STUDY; RATING SCALE;

EID: 33645777978     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/153331750602100208     Document Type: Article

References (50)

1. Liu L, Guo XE, Zhou YQ, et al.: Prevalence of dementia in China. Dement Geriatr Cogn Disord. 2003; 15: 226-230.
2. Knopman DS, Boeve BF, Petersen RC: Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc. 2003; 78: 1290-1308.
3. Stern RG, Mohs RC, Davidson M, et al.: A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994; 151: 390-396.
4. Schmeidler J, Mohs RC, Aryan M: Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer disease. Alzheimer Dis Assoc Disord. 1998; 12: 146-151.
5. Small BJ, Herlitz A, Fratiglioni L, et al.: Cognitive predictors of incident Alzheimer's disease: A prospective longitudinal study. Neuropsychology. 1997; 11: 413-420.
6. Albert MS, Moss MB, Tanzi R, et al.: Preclinical prediction of AD using neuropsychological tests. J Int Neuropsych Soc. 2001; 78: 631-639.
7. Chen P, Ratcliff G, Belle SH, et al.: Patterns of cognitive decline in presymptomatic Alzheimer's disease: A prospective community study. Arch Gen Psychiatry. 2001; 58: 853-858.
8. Ercoli LM, Siddarth P, Dunkin JJ, et al.: MMSE items predict cognitive decline in persons with genetic risk for Alzheimer's disease. J Geriatr Psychiatry Neurol 2003; 16: 67-73.
9. Faber-Langendoen K, Morris JC, Knesevich JW, et al.: Aphasia in senile dementia of the Alzheimer type. Ann Neurol 1988; 23: 365-370.
10. Boller F, Becker JT, Holand AL, et al.: Predictors of decline in Alzheimer's disease. Cortex. 1991; 27: 9-17.
11. Eslinger PJ, Swan GE, Carmelli D: Changes in Mini-Mental State Exam in community-dwelling older persons over 6 years: Relationship to health and neuropsychological measures. Neuroepidemiology. 2003; 22: 23-30.
12. Holtzer R, Wegesin DJ, Albert SM, et al.: The rate of cognitive decline and risk of reaching clinical milestones in Alzheimer's disease. Arch Neurol. 2003; 60: 1137-1142.
13. Burns A, Jacoby R, Levy R: Progression of cognitive impairment in Alzheimer's disease. J Am Geriatr Soc. 1991; 39: 39-45.
14. Hui JS, Wilson RS, Bennett DA, et al.: Rate of cognitive decline and mortality in Alzheimer's disease. Neurology. 2003; 61: 1356-1361.
15. Wilson RS, Beckett LA, Bienias JL, et al.: Terminal decline in cognitive function. Neurology. 2003; 60: 1782-1787.
16. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol. 1993; 34: 752-754.
17. Poirier J, Davignon J, Boutillier D, et al.: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993; 342(8873): 697-699.
18. Li G, Silverman JM, Altstiel LD, et al.: Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. Genet Epidemiol. 1996; 13: 285-298.
19. Burlinson S, Burns A, Mann D, et al.: Effect of apolipoprotein E status on clinical features of dementia. Int J Geriatr Psychiatry. 1998; 13: 177-185.
20. Mak YT, Chiu H, Woo J, et al.: Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. Neurology. 1996; 46: 146-149.
21. Poirier J: Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann N Y Acad Sci. 2000; 924: 81-90.
22. Bennett DA, Wilson RS, Schneider JA, et al.: Apolipoprotein E epsilon 4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology. 2003; 60: 246-252.
23. Petersen RC, Smith GE, Ivnik RJ, et al.: Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995; 273: 1274-1278.
24. Lange KL, Bondi MW, Salmon DP, et al.: Decline in verbal memory during preclinical Alzheimer's disease-Examination of the effects of APOE genotype. J Int Neuropsychol Sci. 2002; 8: 943-955.
25. Bretsky P, Guralnik JM, Launer L, et al.: The role of Apo-E epsilon 4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology. 2003; 60: 1077-1081.
26. Lavretsky H, Ercoli L, Siddarth P, et al.: Apolipoprotein epsilon 4 allele status, depressive symptoms, and cognitive decline in middle-aged and elderly persons without dementia. Am J Geriatr Psychiatry. 2003; 11: 667-673.
27. Holmes C, Levy R, McLoughlin DM, et al.: Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996; 61: 580-583.
28. Kurz A, Egensperger R, Haupt M, et al.: Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology. 1996; 47: 440-443.
29. Murphy GM Jr, Taylor J, Kraemer HC, et al.: No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry. 1997; 154: 603-608.
30. Dal Forno G, Carson KA, Brookmeyer R, et al.: APOE genotype and survival in men and women with Alzheimer's disease. Neurology. 2002; 58: 1045-1050.
31. Scarmeas N, Brandt J, Albert M, et al.: Association between the APOE genotype and psychopathological symptoms in Alzheimer's disease. Neurology. 2002; 58: 1182-1188.
32. Hirono N, Hashimoto M, Yasuda M, et al.: Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon E allele. J Neuropsychiatry Clin Neurosci. 2003; 15: 354-358.
33. Ewbank DC: The APOE gene and differences in life expectancy in Europe. J Gerontol A Biol Sci Med Sci. 2004; 59: 16-20.
34. Hong Kong 2001 Population Census Thematic Report-Older Persons. Hong Kong Special Administrative Region: Census and Statistics Department, 2002.
35. McKhann G, Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34: 939-944.
36. Hughes CP, Berg L, Danziger WL, et al.: A new clinical scale for the staging of dementia: Br J Psychiatry. 1982; 140: 556-572.
37. Morris JC: Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeratr. 1997; 9(suppl 1): 173-176.
38. Mattis S: Mental status examination for organic mental syndrome in the elderly patient. In Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians. New York: Grune & Stratton, 1976.
39. Chan AS, Choi MK, Salmon DP: The effects of age, education and gender on the Mattis Dementia Rating Scale performance of elderly Chinese and American individuals. J Gerontol B Psychol Soc Sci. 2001; 56: 356-363.
40. Chan AS, Choi A, Chiu H, et al.: Clinical validity of the Chinese version of Mattis Dementia Rating Scale in differentiating dementia of Alzheimer's type in Hong Kong. J Int Neuropsychol Soc. 2003; 9: 45-55.
41. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.
42. Chiu HFK, Lee HC, Chung WS, et al.: Reliability and validity of the Cantonese version of the Mini-Mental State Examination-A preliminary study. J Hong Kong Coll Psychiatrists. 1994; 4(suppl 2): 25-28.
43. Au A, Chan AS, Chiu H: Verbal learning in Alzheimer's dementia. J Int Neuropsychol Soc. 2003; 9: 363-375.
44. Mok EHL, Lam LCW, Chiu HFK: Category verbal fluency test in Chinese subjects with Alzheimer's disease. Dement Geriatr Cogn Disord. 2004 (in press).
45. Tsukamoto K, Watanabe T, Matsushima T, et al.: Determination by PRC-RFLP of apo E genotype in a Japanese population. J Lab Clin Med. 1993; 121: 598-602.
46. Morris JC, Edland S, Clark C, et al.: The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993; 43: 2457-2465.
47. Han L, Cole M, Bellavance F, et al.: Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Examination: A meta-analysis. Int Psychogeriatr. 2000; 12: 231-247.
48. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer's disease: Therapeutic implications. Age Ageing. 2003; 32: 200-204.
49. Storandt M, Grant EA, Miller JP, et al.: Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002; 59: 1034-1041.
50. Doraiswamy PM, Leon J, Cummings JL, et al.: Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2002; 57: M173-M177.